Shares of Dr Martens surged sharply following the release of the company’s annual financial results, driven by significant profit growth attributed to cost reductions and increased sales. In early trading, the footwear manufacturer’s shares climbed 8.5% to 69.8 pence, marking a 22.1% increase compared to the previous year, although they remain down 7.4% since January as investors await further developments in the company's turnaround strategy.

For the fiscal year ending in March, Dr Martens reported a pre-tax profit of £32.7 million, a substantial rise from £8.8 million reported in the prior year, reflecting a 270% increase. This surge was largely supported by a £17 million reduction in the cost of sales, which decreased to £258.9 million. The company attributed these savings primarily to lower global ocean freight rates, which helped improve overall margins.

In addition to cost efficiencies, Dr Martens experienced a 19% growth in shoe sales. The company noted that renewed consumer interest in its classic footwear, combined with a strategic emphasis on selling at full price rather than discounting, contributed to this uplift. Despite these gains, Dr Martens maintained its dividend at 2.5 pence per share, signaling a cautious approach amid ongoing efforts to solidify its market position.

While the strong financial performance has been well received in the market, some investors remain cautious as they await further details on the company’s broader plans to sustain growth and enhance profitability.